Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Keywords: CANCER ; CANCER CELLS ; CELLS ; INHIBITOR ; tumor ; BLOOD ; CELL ; Germany ; KINASE ; MODEL ; PATHWAY ; imaging ; SYSTEM ; SYSTEMS ; liver ; GENE ; PROTEIN ; PROTEINS ; METABOLISM ; TUMORS ; NUCLEAR-MEDICINE ; PATIENT ; MECHANISM ; mechanisms ; protein kinase ; PROTEIN-KINASE ; treatment ; SIGNAL ; ANTITUMOR-ACTIVITY ; TARGET ; metastases ; RESECTION ; CANCER-CELLS ; positron emission tomography ; POSITRON-EMISSION-TOMOGRAPHY ; tomography ; GLUCOSE ; PET ; LIVER METASTASES ; imatinib ; SARCOMA ; nuclear medicine ; AKT ; GASTROINTESTINAL STROMAL TUMORS ; INHIBITORS ; targeting ; ONCOLOGY ; RE ; monitoring ; INCREASE ; F-18-FDG ; TRANSPORTER ; KINASE INHIBITORS ; LEVEL ; ENZYME ; NUCLEAR ; uptake ; female ; UNIT ; KINASE INHIBITOR ; FDG ; EMISSION-TOMOGRAPHY ; ANTITUMOR ACTIVITIES ; surgical resection ; SARCOMAS ; mTOR ; MEDICINE ; UPSTREAM ; PROTEIN-KINASE-B ; antitumor activity ; German ; EMISSION ; emission tomography ; CASCADE ; GIST ; m-TOR inhibitor ; positron ; protein kinase B ; treatment monitoring
    Abstract: Several mechanisms may influence the enhanced glucose uptake in cancer cells, including upregulation of glucose transporters, increase in the hexokinase activity and the protein kinase B, also called Akt, which appears to play key role in the control of glucose metabolism together with proteins which are involved in the signal cascade pathway, such as the mammalian target of rapamycin (mTOR). It has been demonstrated in patients with gastrointestinal stromal tumors (GIST) and other sarcomas who received treatment with imatinib that PET with F-18-FDG is appropriate for treatment monitoring. Data suggest that F-18-FDG monitoring may be used for monitoring not only imatinib but also other kinase inhibitors. A 36-year-old female patient with metastasized desmoplastic small round cells tumor after a broad surgical resection of the tumor area and due to related enzyme findings, was treated with the mTOR-inhibitor everolimus (Certican((R)), Novartis, Basel, Switzerland) at an initial dose of 3 x 0.5 mg per day targeting at a blood level of 〉 11 ng/ml. A baseline F-18-FDG-PET demonstrated an enhanced FDG uptake in three large liver metastases and in another metastatic lesion in the pelvic area. A dynamic F-18-FDG-PET study performed six weeks later, demonstrated non-response to the mTOR-inhibitor. Despite the antiproliferative activity of mTOR-inhibitors in experimental model systems, its antitumor activity in patients may be limited. In conclusion, F-18-FDG-PET seems to be a promising method for monitoring the therapeutic effect of mTOR-inhibitors
    Type of Publication: Journal article published
    PubMed ID: 17684580
    Signatur Availability
    BibTip Others were also interested in ...
  • 2
    Keywords: COMBINATION ; Germany ; DIAGNOSIS ; FOLLOW-UP ; imaging ; INFORMATION ; SITE ; DIFFERENTIATION ; NUCLEAR-MEDICINE ; PATIENT ; CONTRAST ; MRI ; MAGNETIC-RESONANCE ; magnetic resonance imaging ; chemotherapy ; RECURRENCE ; RESECTION ; positron emission tomography ; POSITRON-EMISSION-TOMOGRAPHY ; tomography ; TRANSFORMATION ; MALIGNANT TRANSFORMATION ; PET ; nuclear medicine ; GLIOMAS ; MULTIFORME ; ORDER ; radiology ; BRAIN-TUMORS ; CONTRAST ENHANCEMENT ; GLIOMA ; GRADE ; F-18-FDG ; ENHANCEMENT ; F-18 FLUORODEOXYGLUCOSE ; methods ; NUCLEAR ; LOW-GRADE GLIOMA ; glioblastoma multiforme ; GLIOBLASTOMA-MULTIFORME ; GLIOBLASTOMA ; EMISSION-TOMOGRAPHY ; MEDICINE ; LOW-GRADE ; EMISSION ; DETECT ; F-18-FDG-PET ; Ga-68-bombesin-PET ; Low grade gliomas
    Abstract: Treatment of gliomas is multimodal. Magnetic resonance imaging (MRI) in the posttreatment course is of limited value due to therapy-induced changes. In low-grade gliomas (LGG) malignant transformation is of special interest. Our patients and methods were as follows: In nine consecutive patients with LGG we examined the role of bombesin labelled with gallium-68 (Ga-68-bombesin) studied with positron emission tomography (PET), in addition to fluoro-18-fluorodeoxyglucose (F-18-FDG) in the differential diagnosis of tumour recurrence versus malignant transformation. We used Ga-68-bombesin combined with F-18-FDG-PET in these patients with suspicious new contrast enhancement at the original tumour site or resection cavity in MRI. Eight patients were operated. In one patient, tumour recurrence was most likely as shown by the PET findings and chemotherapy was administered. Our results have shown that in this last mentioned patient after the follow-up period, MRI contrast enhancement was definitively regressive. In the operated patients the tumour was graded as glioblastoma multiforme, gliosarcoma and WHO grade III tumour. In two patients histological grading confirmed the PET findings without malignant transformation. In all of the 9 patients the combination of Ga-68-bombesin and F-18-FDG-PET predicted correctly malignant transformation or recurrence of the initial tumour grade which shows that Ga-68-bombesin-PET can provide additional important information to detect a malignant transformation. In conclusion it is crucial for the patient to differentiate the nature of the new lesion in order to endorse an aggressive or non-aggressive treatment
    Type of Publication: Journal article published
    PubMed ID: 19081856
    Signatur Availability
    BibTip Others were also interested in ...
  • 3
    Keywords: CANCER ; radiotherapy ; SURVIVAL ; tumor ; carcinoma ; Germany ; CT ; FOLLOW-UP ; imaging ; INFORMATION ; QUANTIFICATION ; SYSTEM ; SYSTEMS ; METABOLISM ; TUMORS ; ACCURACY ; SURGERY ; NUCLEAR-MEDICINE ; PATIENT ; MRI ; molecular imaging ; RECURRENCE ; POSITRON-EMISSION-TOMOGRAPHY ; HEAD ; PET ; FLOW-CYTOMETRY ; nuclear medicine ; NECK-CANCER ; molecular ; RE ; F-18-FDG ; NUCLEAR ; MASS ; RADIOPHARMACEUTICALS ; FDG-PET ; MEDICINE ; quantitative ; SCAN
    Abstract: PET and PET/CT are the procedures of choice for molecular imaging in the head and neck area. The current data of the literature show, that functional imaging with fluorine-18-deoxyglucose (F-18-FDG) provides the possibility to obtain information about the viability of malignant lesions. The use of hybrid systems, PET/CT, enables physicians to assess both, morphology and function, and achieve a high diagnostic accuracy exceeding 90%. PET with F-18-FDG is the most sensitive method to detect tumor recurrence. However, false positive results must be considered due to unspecific changes following treatment, especially radiotherapy. The use of quantitative PET scans as well as the application of a second tracer, enhance the capability of PET to assess questionable masses more accurately. Follow up examinations with PET and F-18-FDG provide data about early changes in the tumor metabolism due to chemotherapeutic treatment. Studies in patients undergoing surgery and radiotherapy demonstrated, that PET with F-18-FDG can be used for the prediction of individual survival
    Type of Publication: Journal article published
    PubMed ID: 18392219
    Signatur Availability
    BibTip Others were also interested in ...
  • 4
    Keywords: ANGIOGENESIS ; tumor ; GENE-EXPRESSION ; POSITRON-EMISSION-TOMOGRAPHY ; PET ; F-18-FDG ; MDA-MB-231 breast cancer cells ; FDG ; BONE METASTASES ; cell invasion ; INTEGRIN ALPHA-V-BETA-3 ; Cilengitide ; PRIMARY CHEMOTHERAPY ; RGD PEPTIDES ; SIALOPROTEIN
    Abstract: The purpose of this study was the assessment of the feasibility of dynamic positron emission tomography (PET) studies with fluorine-18 fluorodeoxyglucose (F-18-FDG) to quantify effects of the cyclic Arg-Gly-Asp peptide cilengitide, which targets the alpha v beta 3 and alpha v beta 5 integrin receptors in rats with breast cancer bone metastases. Rats were inoculated with MDA-MB-231 breast cancer cells, followed by the development of lytic lesions in the hind leg. Rats with lytic lesions were treated with cilengitide five times weekly on a continuous basis from days 30 to 55 after tumor cell inoculation. Dynamic PET studies with 18F-FDG were performed in untreated (n=9), controlled (n=4) and treated rats (n=6). The data were assessed using learning-machine two-tissue compartmental analysis. The F-18-FDG kinetic parameters obtained by two-tissue compartmental model learning-machine showed significant differences when individual parameters were compared between the control group and treated animals. Quantitative assessment of the tracer kinetics and the application of classification analysis to the data provided us with evidence to identify those tumors that demonstrated effect of cilengitide treatment. The transport rate K1 and the phosphorylation rate k3 were significantly different (P=0.033 and 0.038, respectively). Classification analysis based on support vector machines ranking feature elimination of the combination of PET parameters revealed an overall accuracy of 80.0% between treated animals and the control group. We were able to identify 83.3% treated animals compared with the control group based on k2 and VB. In conclusion, the results revealed that cilengitide treatment of experimental breast cancer bone metastases had a significant therapeutics impact on F-18-FDG kinetics
    Type of Publication: Journal article published
    PubMed ID: 21512659
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...